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The article Efficacy and Safety of Switching to Ixekizumab
in Etanercept Non-Responders: A Subanalysis from Two
Phase III Randomized Clinical Trials in Moderate-to-Sev-
ere Plaque Psoriasis (UNCOVER-2 and -3) written by
Andrew Blauvelt, Kim A. Papp, Christopher E. M. Grif-
fiths, Luis Puig, Jamie Weisman, Yves Dutronc, Lisa
Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin
was originally published Online First without open access.
After publication in volume 18, issue 2, pages 273–280 the
author decided to opt for Open Choice and to make the
article an open access publication. Therefore, the copyright
of the article has been changed to  The Author(s) 2017
and the article is forthwith distributed under the terms of
the Creative Commons Attribution Attribution-NonCom-
mercial 4.0 International License (http://creativecommons.
org/licenses/by-nc/4.0/), which permits any noncommercial
use, duplication, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, a link is
provided to the Creative Commons license and any chan-
ges made are indicated.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and
indicate if changes were made.
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